The shift at CDMI 2026 was not about which AI tools clinical data teams are adopting. It was about how they talk about those tools now: less enthusiasm about automation replacing judgment, more attention to what happens when it gets something wrong.
That practical turn matters because the regulatory floor is rising. FDA’s January 2025 draft guidance on AI supporting regulatory decision-making for drugs and biologics puts human oversight at the center of any acceptable workflow, and FDA’s December 2024 final guidance on predetermined change control plans for AI-enabled device software requires manufacturers to specify in advance how models can change and under what conditions. Neither document rewards teams that treat AI output as self-validating. Together they signal that regulators want to see explicit validation logic and documented human checkpoints, not just accuracy claims backed by internal testing.
What CDMI surfaced is that clinical data professionals are absorbing this. The conference conversation centered on clinical context, not compute: whether an AI flag makes sense given what a particular protocol actually measures, whether the person reviewing the output has enough domain knowledge to push back, and whether the validation evidence would hold up under regulatory scrutiny. That is a narrower and more useful set of questions than the broader “can AI improve data quality” framing that dominated earlier cycles. It also reflects a realistic read of where failures tend to occur. A model that performs well on training data from one therapeutic area can produce systematically misleading signals when applied to a different protocol population, and no amount of confidence scoring fixes a mismatch that nobody checked for.
The practical consequence for ops teams is that trust in an AI-assisted data workflow now has to be earned trial by trial, not carried over from a vendor validation package. The specific marker worth watching: whether sponsors start requiring indication-specific validation documentation from data vendors as a contract term, not as an afterthought during audit prep.
Source link: https://www.eclinicalsol.com/blog/takeaways-from-cdmi-2026/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
